Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Articles|August 16, 2019
New Tumor-Agnostic Oncology Drug Approval Tops SPT Week in Review
Author(s)SPT Staff
Top news of the week from Specialty Pharmacy Times.
Advertisement
5. FDA Committee Recommends Approval of Descovy for HIV PrEP Indication
An FDA committee voted 16 to 2 to recommended emitricitabine 200 mg and tenofovir alafenamide 25 mg tablets (Descovy, Gilead) for a HIV pre-exposure prophylaxis indication.
4. Study Examines Familial Risk Associated with Blood Cancers
The number of first-degree relatives affected by blood cancer and age of diagnosis may contribute to the likelihood of a family member’s risk of being diagnosed with the same disease.
3. Oncology Specialty Pharmacy Teams Help Ease Financial Burden for Patients
An analysis of a quality improvement project at an oncology specialty pharmacy showed that pharmacist interventions can reduce financial toxicity for patients.
2. FDA Grants Breakthrough Therapy Designation to Acalabrutinib for CLL
If approved, acalabrutinib (Calquence, AstraZeneca) will offer a chemotherapy-free treatment option for adults with chronic lymphocytic leukemia.
1. FDA Approves First Oncology Drug Targeting Both ROS1, NTRK Gene Fusions
Officials with the FDA have granted approval to entrectinib (Rozlytrek, Genentech) for 2 different cancer indications.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Phase 3 Trial Finds Adding Monoclonal Antibody to mRNA Vaccine Improves COVID-19 Immunization Tolerability
2
Semaglutide Normalized Liver Fat in Most Adults With Obesity
3
Intensive BP Control Cuts CV Risk Regardless of CKD Status
4
When Parents Decline the Vitamin K Shot: What Every Pharmacist Needs to Know
5